WEBSITE BSE:544250 NSE: SANOFICONR Inc. Year: 2023 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:58
​Sanofi Consumer Healthcare India Limited (SCHIL) is a prominent player in India\'s fast-moving consumer healthcare (FMCH) sector. Incorporated on May 10, 2023, SCHIL emerged as a separate entity following the demerger of Sanofi India Limited\'s (SIL) consumer healthcare division, effective from June 1, 2024 . The demerger aimed to unlock growth potential by allowing both the pharmaceutical and consumer healthcare businesses to operate independently, each focusing on their respective markets .​The demerger has positioned SCHIL to leverage e...Read More
​Sanofi Consumer Healthcare India Limited (SCHIL) is a prominent player in India\'s fast-moving consumer healthcare (FMCH) sector. Incorporated on May 10, 2023, SCHIL emerged as a separate entity following the demerger of Sanofi India Limited\'s (SIL) consumer healthcare division, effective from June 1, 2024 . The demerger aimed to unlock growth potential by allowing both the pharmaceutical and consumer healthcare businesses to operate independently, each focusing on their respective markets .​The demerger has positioned SCHIL to leverage emerging consumer trends and digital innovations, aiming to enhance customer experiences and address unmet healthcare needs in India . By focusing on consumer-centric strategies and e-commerce capabilities, SCHIL is poised to strengthen its presence in India\'s dynamic consumer healthcare market. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹10583 Cr.
Stock P/E 58.5
P/B 27.6
Current Price ₹4595.3
Book Value ₹ 166.7
Face Value 10
52W High ₹5954
Dividend Yield 0%
52W Low ₹ 3950.5
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 210 | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 |
| Other Income | 1 | 3 | 3 | 1 | 4 | 5 | 5 | 6 | 3 | 5 |
| Total Income | 212 | 227 | 225 | 173 | 164 | 176 | 178 | 227 | 237 | 256 |
| Total Expenditure | 116 | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 |
| Operating Profit | 96 | 92 | 85 | 64 | 67 | 67 | 69 | 76 | 88 | 94 |
| Interest | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 3 |
| Exceptional Income / Expenses | 0 | -2 | 0 | -24 | -1 | -3 | 0 | 7 | 0 | 0 |
| Profit Before Tax | 95 | 90 | 84 | 39 | 61 | 63 | 67 | 79 | 84 | 91 |
| Provision for Tax | 24 | 22 | 21 | 10 | 16 | 19 | 17 | 18 | 21 | 24 |
| Profit After Tax | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 67 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 67 |
| Adjusted Earnings Per Share | 31 | 27.2 | 313.5 | 12.6 | 19.6 | 19.3 | 21.7 | 26.4 | 27.3 | 28.9 |
| #(Fig in Cr.) | Dec 2023 | Dec 2024 | TTM |
|---|---|---|---|
| Net Sales | 555 | 725 | 879 |
| Other Income | 4 | 13 | 19 |
| Total Income | 560 | 738 | 898 |
| Total Expenditure | 337 | 454 | 570 |
| Operating Profit | 223 | 284 | 327 |
| Interest | 0 | 4 | 3 |
| Depreciation | 2 | 5 | 11 |
| Exceptional Income / Expenses | -2 | -28 | 7 |
| Profit Before Tax | 219 | 247 | 321 |
| Provision for Tax | 54 | 66 | 80 |
| Profit After Tax | 165 | 181 | 241 |
| Adjustments | 0 | 0 | 0 |
| Profit After Adjustments | 165 | 181 | 241 |
| Adjusted Earnings Per Share | 824.5 | 78.7 | 104.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 31% | 0% | 0% | 0% |
| Operating Profit CAGR | 27% | 0% | 0% | 0% |
| PAT CAGR | 10% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -7% | NA% | NA% | NA% |
| ROE Average | 79% | 84% | 84% | 84% |
| ROCE Average | 104% | 105% | 105% | 105% |
| #(Fig in Cr.) | Dec 2023 | Dec 2024 |
|---|---|---|
| Shareholder's Funds | 208 | 273 |
| Minority's Interest | 0 | 0 |
| Borrowings | 0 | 0 |
| Other Non-Current Liabilities | 6 | 22 |
| Total Current Liabilities | 130 | 252 |
| Total Liabilities | 344 | 547 |
| Fixed Assets | 5 | 29 |
| Other Non-Current Assets | 3 | 4 |
| Total Current Assets | 335 | 513 |
| Total Assets | 344 | 547 |
| #(Fig in Cr.) | Dec 2023 | Dec 2024 |
|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 2 |
| Cash Flow from Operating Activities | -0 | 439 |
| Cash Flow from Investing Activities | 0 | 2 |
| Cash Flow from Financing Activities | 2 | -116 |
| Net Cash Inflow / Outflow | 2 | 325 |
| Closing Cash & Cash Equivalent | 2 | 327 |
| # | Dec 2023 | Dec 2024 |
|---|---|---|
| Earnings Per Share (Rs) | 824.5 | 78.7 |
| CEPS(Rs) | 833.5 | 80.65 |
| DPS(Rs) | 50 | 55 |
| Book NAV/Share(Rs) | 923 | 118.26 |
| Core EBITDA Margin(%) | 37.87 | 35.76 |
| EBIT Margin(%) | 37.96 | 33.13 |
| Pre Tax Margin(%) | 37.96 | 32.62 |
| PAT Margin (%) | 28.54 | 23.92 |
| Cash Profit Margin (%) | 28.86 | 24.51 |
| ROA(%) | 48.01 | 40.67 |
| ROE(%) | 89.33 | 79.28 |
| ROCE(%) | 105.64 | 104.33 |
| Receivable days | 19.97 | 10.93 |
| Inventory Days | 61.03 | 33.16 |
| Payable days | 144.17 | 127.78 |
| PER(x) | 0 | 62.61 |
| Price/Book(x) | 0 | 41.66 |
| Dividend Yield(%) | 0 | 1.12 |
| EV/Net Sales(x) | 0 | 15.19 |
| EV/Core EBITDA(x) | 0 | 38.81 |
| Net Sales Growth(%) | 0 | 30.45 |
| EBIT Growth(%) | 0 | 14.32 |
| PAT Growth(%) | 0 | 9.76 |
| EPS Growth(%) | 0 | -90.46 |
| Debt/Equity(x) | 0 | 0 |
| Current Ratio(x) | 2.58 | 2.04 |
| Quick Ratio(x) | 1.84 | 1.87 |
| Interest Cover(x) | 0 | 64.28 |
| Total Debt/Mcap(x) | 0 | 0 |
| # | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 60.4 | 60.4 | 60.4 | 71.27 | 71.27 | 71.27 | 71.27 |
| FII | 5.22 | 4.42 | 4.53 | 3.24 | 2.93 | 2.83 | 2.75 |
| DII | 23.83 | 25.15 | 24.9 | 16.89 | 17.21 | 17.33 | 17.58 |
| Public | 10.56 | 10.04 | 10.17 | 8.6 | 8.59 | 8.57 | 8.4 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 1.39 | 1.39 | 1.39 | 1.64 | 1.64 | 1.64 | 1.64 |
| FII | 0.12 | 0.1 | 0.1 | 0.07 | 0.07 | 0.07 | 0.06 |
| DII | 0.55 | 0.58 | 0.57 | 0.39 | 0.4 | 0.4 | 0.4 |
| Public | 0.24 | 0.23 | 0.23 | 0.2 | 0.2 | 0.2 | 0.19 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
